What changed from existing technology?
This study compared two treatments for older patients with chronic lymphocytic leukemia. One treatment, ibrutinib-venetoclax, showed better long-term results than the other, chlorambucil-obinutuzumab, with fewer patients needing more treatment later.
This is the first long-term study to evaluate the effectiveness and safety of ibrutinib-venetoclax in older patients with chronic lymphocytic leukemia, showing sustained benefits over time.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 2
to inform optimal first-line treatment for individual patients with chronic lymphocytic leukemia (CLL). We report long-term outcomes of ibrutinib-venetoclax
Abstract ↗OpenAlex author affiliations: Johnson & Johnson (Switzerland), Johnson & Johnson (United States), Johnson & Johnson (Ireland)
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
Ibrutinib-venetoclax may be considered a first-line treatment option for older patients with chronic lymphocytic leukemia due to its long-term benefits and reduced need for second-line therapy.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.
Evidence and sources
View paper and author affiliations
Open original researchFirst-line ibrutinib-venetoclax in chronic lymphocytic leukemia: GLOW 67-month results and grade 3/4 adverse event-free progression-free survivalLeukemia · Published 2026-10-02 ↗Author institutions and listed legal entities are separated; only verified exchange and ticker data is linked.